Literature DB >> 8077711

Development of clinical disease in cats experimentally infected with feline immunodeficiency virus.

R V English1, P Nelson, C M Johnson, M Nasisse, W A Tompkins, M B Tompkins.   

Abstract

Cats naturally infected with feline immunodeficiency virus (FIV) develop an AIDS-like syndrome whereas experimentally infected cats do not. To investigate the role of cofactors in the development of this disease in cats, 7 specific pathogen-free (SPF) and 12 random-source (RS) cats were infected with FIV. Over 4 years, infected cats developed similar phenotypic and functional immune abnormalities characterized by early and chronic inversion of CD4+:CD8+ cell ratios and significantly decreased mitogen responses compared with controls. Beginning 18-24 months after infection, 10 RS cats developed chronic clinical disease typical of feline AIDS, including stomatitis and recurrent upper respiratory disease; 4 SPF cats also developed chronic clinical disease, 2 with neurologic disease and 2 with B cell lymphomas. Thus, immunologic background is important in the type of disease that develops in cats infected with FIV, and FIV represents a promising animal model for studying the immunopathogenesis of AIDS in humans.

Entities:  

Mesh:

Year:  1994        PMID: 8077711     DOI: 10.1093/infdis/170.3.543

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding.

Authors:  A de Parseval; D L Lerner; P Borrow; B J Willett; J H Elder
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Suppression of immunodeficiency virus-associated neural damage by the p75 neurotrophin receptor ligand, LM11A-31, in an in vitro feline model.

Authors:  Rick B Meeker; Winona Poulton; Wen-hai Feng; Lola Hudson; Frank M Longo
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-10       Impact factor: 4.147

3.  Immunopathologic changes in the thymus during the acute stage of experimentally induced feline immunodeficiency virus infection in juvenile cats.

Authors:  J C Woo; G A Dean; N C Pedersen; P F Moore
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus).

Authors:  H L Jordan; J Howard; W A Tompkins; S Kennedy-Stoskopf
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

6.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection.

Authors:  L J Diehl; C K Mathiason-Dubard; L L O'Neil; E A Hoover
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Evidence for CD8+ antiviral activity in cats infected with feline immunodeficiency virus.

Authors:  C R Jeng; R V English; T Childers; M B Tompkins; W A Tompkins
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.